-
- Description: Human Genome Sciences, Inc. is a biopharmaceutical company with a pipeline of compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and human immunodeficiency virus/acquired immunodeficiency syndrome (Hiv/ Aids). Human Genome Sciences has an active preclinical development program, including human protein and antibody drugs discovered through genomics-based research, and new long-acting versions of existing proteins created using its albumin fusion technology. All but one of the Company's drugs that are in clinical trials is derived from genomics-based research. As of December 31, 2005, its drugs in clinical development are Albuferon; Lymphostat-B; Abthrax ; Hgs-Etr; Hgs-Etr2 and Hgs-Tr2j, and Ccr5 mab. The other drug in clinical trials is an albumin fusion protein. Human Genome Sciences, Inc. specializes in the application of science and great medicine to bring innovative drugs to patients with unmet medical needs. The company produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities. General Information Year established 1996
- More Products No Keyword available...
- About Owner No Owner Type Present...
-
